These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1010 related articles for article (PubMed ID: 32267987)

  • 21. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.
    Li YC; Bai WZ; Hashikawa T
    J Med Virol; 2020 Jun; 92(6):552-555. PubMed ID: 32104915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century.
    da Costa VG; Moreli ML; Saivish MV
    Arch Virol; 2020 Jul; 165(7):1517-1526. PubMed ID: 32322993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects.
    Wielgat P; Rogowski K; Godlewska K; Car H
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adaptive immunity against SARS-CoV-2].
    Combadière B
    Med Sci (Paris); 2020 Oct; 36(10):908-913. PubMed ID: 32960167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
    Yashavantha Rao HC; Jayabaskaran C
    J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.
    Kellam P; Barclay W
    J Gen Virol; 2020 Aug; 101(8):791-797. PubMed ID: 32430094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
    İnandıklıoğlu N; Akkoc T
    Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Strategies for vaccine development of COVID-19].
    Yang L; Tian D; Liu W
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
    Zhou G; Zhao Q
    Int J Biol Sci; 2020; 16(10):1718-1723. PubMed ID: 32226289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
    Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
    JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.
    Xu P; Sun GD; Li ZZ
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
    Ni L; Ye F; Cheng ML; Feng Y; Deng YQ; Zhao H; Wei P; Ge J; Gou M; Li X; Sun L; Cao T; Wang P; Zhou C; Zhang R; Liang P; Guo H; Wang X; Qin CF; Chen F; Dong C
    Immunity; 2020 Jun; 52(6):971-977.e3. PubMed ID: 32413330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.